Abstract
Pediatric pts with metastatic or recurrent solid tumors often relapse even when remissions are consolidated with high dose chemotherapy and autologous hematopoietic cell transplant (HCT). We previously showed dendritic cell (DC) based tumor vaccines to be safe and produce anti-tumor responses in children with refractory solid tumors. Experimental evidence indicates that the period of lymphopenia that occurs after HCT may be an opportune time to improve the immune response to self tumor. Furthermore, a DC based tumor vaccine may be most effective when residual disease burden is minimal, as in the period immediately after HCT.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
